<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1535">
  <stage>Registered</stage>
  <submitdate>9/08/2006</submitdate>
  <approvaldate>16/01/2007</approvaldate>
  <actrnumber>ACTRN12607000050459</actrnumber>
  <trial_identification>
    <studytitle>Chlorhexidine in preterm babies</studytitle>
    <scientifictitle>Use of chlorhexidine as a topical antiseptic for the prevention of nosocomial sepsis in premature neonates &lt; 29 weeks: a blinded randomised controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Nosocomial infection in preterm babies</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Aqueous chlorhexidine 0.5% (intervention group) applied topically. The solution is applied prior to each invasive procedure for both control and intervention groups.</interventions>
    <comparator>Aqueous chorhexidine 0.015% (control group) applied topically. The solution is applied prior to each invasive procedure for both control and intervention groups.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of episodes of nosocomial infection in infants &lt; 29 weeks</outcome>
      <timepoint>During stay in the neonatal intensive care unit (NICU)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Skin integrity</outcome>
      <timepoint>Before and after application of topical antiseptic</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Episodes of antibiotic use at discharge from NICU  </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Antibiotic days at discharge from NICU </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of ventilation at discharge from NICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Omphalitis at discharge from NICU </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Necrotizing enterocolitis (NEC) at discharge from NICU </outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Osteomyelitis at discharge from NICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Length of stay in a tertiary centre</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality before discharge from NICU</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Developmental outcomes at 12 months corrected age</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inborn infants &lt; 29 weeks. Informed parental consent.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>29</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Parental consent not given. Ex utero transfer, unlikely to survive major congenital anomaly.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Control / intervention solutions - the solution is pre number containers supplied by pharmacist</concealment>
    <sequence>Randomisation of  control / intervention solutions performed using the Statistical Package for Social Sciences (SPSS) solutions stratified for use in infants from two cohorts &lt; 27 weeks &amp; 27 - 28 weeks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Babies / families / clinicians / investigators / developmental paediatrician are blinded</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/04/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>169</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Sandie Bredemeyer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NSW Nurses Midwives Registration Board</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Ester Carman</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Nick Evans</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Shelley Reid</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Strategies for reducing infection are vital in caring for the premature neonate, and include, the use of a topical antiseptic for skin cleansing prior to any invasive procedure that compromises the skin barrier. There is currently little research addressing the issue of what antiseptic solution is best and safest for use in this vulnerable neonatal population. Consequently a wide range of solutions are utilised within the NICU setting</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital - RPA Newborn Care Unit</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>X04-0175</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sandie Bredemeyer</name>
      <address>RPA Women and Babies 
Newborn Care Unit
Missenden Rd Camperdown NSW 2050</address>
      <phone>+61 2 95158923 / +61 2 93510505</phone>
      <fax>+61 2 95504375</fax>
      <email>sbredemeyer@nursing.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sandie Bredemeyer</name>
      <address>RPA Women and Babies 
Newborn Care Unit
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 2 95158923 / +61 2 93510505</phone>
      <fax>+61 2 95504375</fax>
      <email>sbredemeyer@nursing.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>